Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke Post published:March 17, 2021 Post category:Press Release
Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK) Post published:March 1, 2021 Post category:Press Release
Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program Post published:February 19, 2021 Post category:Press Release
Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies Post published:February 8, 2021 Post category:Press Release
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule” Post published:February 1, 2021 Post category:Press Release